Bellevue Group AG Invests $1.71 Million in Regenxbio Inc (RGNX)  Paula Ricardo | Aug 17th, 2018
Bellevue Group AG purchased a new stake in shares of Regenxbio Inc (NASDAQ:RGNX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 23,800 shares of the biotechnology company's stock, valued at approximately $1,708,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Amalgamated Bank bought a new position in shares of Regenxbio in the second quarter worth approximately $332,000. Fred Alger Management Inc. bought a new position in shares of Regenxbio in the second quarter worth approximately $933,000. UBS Group AG increased its position in shares of Regenxbio by 71.2% in the first quarter. UBS Group AG now owns 43,251 shares of the biotechnology company's stock worth $1,291,000 after purchasing an additional 17,994 shares during the last quarter. Redmile Group LLC increased its position in shares of Regenxbio by 49.5% in the first quarter. Redmile Group LLC now owns 2,130,972 shares of the biotechnology company's stock worth $63,610,000 after purchasing an additional 705,700 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Regenxbio in the first quarter worth approximately $233,000. Hedge funds and other institutional investors own 71.73% of the company's stock. Get Regenxbio alerts:
Several research analysts recently weighed in on the stock. TheStreet cut shares of Regenxbio from a "c" rating to a "d+" rating in a research report on Friday, August 10th. Barclays upped their price objective on shares of Regenxbio from $48.00 to $83.00 and gave the stock an "overweight" rating in a research report on Monday. ValuEngine upgraded shares of Regenxbio from a "buy" rating to a "strong-buy" rating in a research report on Friday, August 10th. Chardan Capital decreased their price objective on shares of Regenxbio from $130.00 to $127.50 and set a "buy" rating on the stock in a research report on Wednesday, August 8th. Finally, BidaskClub cut shares of Regenxbio from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, July 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of "Buy" and a consensus target price of $74.79.
RGNX stock opened at $65.00 on Friday. The company has a market capitalization of $2.18 billion, a P/E ratio of -26.53, a P/E/G ratio of 8.43 and a beta of -1.16. Regenxbio Inc has a 1-year low of $19.45 and a 1-year high of $85.10.
Regenxbio (NASDAQ:RGNX) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.23 by ($0.93). The firm had revenue of $40.03 million during the quarter, compared to analysts' expectations of $100.00 million. Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. analysts anticipate that Regenxbio Inc will post 2.63 EPS for the current year.
In other Regenxbio news, Director Donald J. Hayden, Jr. sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, June 5th. The stock was sold at an average price of $55.01, for a total value of $825,150.00. Following the completion of the sale, the director now owns 100 shares of the company's stock, valued at $5,501. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link . Also, insider Kenneth T. Mills sold 10,000 shares of the company's stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $47.05, for a total value of $470,500.00. The disclosure for this sale can be found here . In the last ninety days, insiders sold 50,100 shares of company stock valued at $2,907,175. 16.90% of the stock is owned by insiders.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Read More: Market Capitalization in the Stock Market
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX). Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter . Ã‚